Wanbury Launches New Pediatric Cold & Sneezing Products for Coriminic Brand
Wanbury Limited has launched Coriminic CPM Drops and Coriminic NS Nasal Drops to strengthen its Coriminic brand for pediatric use. These launches align with DCGI regulations restricting fixed-dose cold combinations for children under 4. The move aims to capture a share of the ₹861 crore Cold Preparation Liquid market.
The launch of new pediatric-focused products is a positive development for the company and could lead to increased market share in the cold preparation liquid market.
The company is strategically launching new products that comply with regulatory changes, aiming to expand its market share in a significant market segment.
Wanbury Limited (WL) has announced the strategic expansion of its popular Coriminic brand by launching two new products tailored for pediatric use, aligning with recent regulatory changes.
The company has introduced Coriminic CPM Drops (Chlorpheniramine Maleate), designed specifically for children experiencing cold and sneezing symptoms. This formulation excludes decongestants to comply with the Drugs Controller General of India's (DCGI) notification restricting fixed-dose cold combinations for children under 4 years of age.
Alongside Coriminic CPM Drops, Wanbury is also launching Coriminic NS (Normal Saline) Nasal Drops. This non-systemic nasal decongestant provides localized relief for nasal congestion in children, enabling physicians to offer compliant treatment options.
These launches are a direct response to DCGI advisories limiting the use of fixed-dose combinations like Chlorpheniramine + Phenylephrine in children under 4 due to safety concerns. This strategic move aims to position Wanbury to capture a significant share of the ₹861 crore Cold Preparation Liquid market and navigate the regulatory landscape effectively.
Coriminic CPM Drops offer targeted relief from allergic symptoms such as severe cold, blocked nose, and sneezing, while supporting rational prescribing practices in pediatric care. This initiative represents a first-of-its-kind India-focused effort to reposition Chlorpheniramine in a safer, indication-driven format for pediatric use.
What to do with a filing like this
Wanbury Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Wanbury Limited. Read the original for the full detail.